Shots:

• Combination of Imbruvica (ibrutinib) & Rituxan (rituximab) approval is the first and only CT free combination treatment in all line of therapies 
• This approval is based on P-III iNNOVATE (PCYC-1127) trial (N=150) assessing (Imbruvica+ Rituxan vs Rituxan alone) where PFS (82% vs 28%) with mPFS as 26.5mos and reduction in disease progression or death by 80% ·
•  Recommended dose for Imbruvica is 420mg PO QD- while Imbruvica will be taken on prior basis before Rituxan

  Ref: Abbvie | Image: AbbVie